Breast Cancer Biomarkers: Utility in Clinical Practice
Current Breast Cancer Reports · 2013-12 · 5 (4) · 284-292
DOI: 10.1007/s12609-013-0125-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Breast Cancer Reports, online erschienen am 25.10.2013. Verfasst von Fanny Le Du und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA ; Department of Medical Oncology, Eugène…. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Breast cancer is a heterogeneous disease. For the past decades, new technical tools have been developed for biomarkers at the DNA, RNA and protein levels to better understand the biology of breast cancer. This progress is essential to classify the disease into clinically relevant subtypes, which may lead to new therapeutic opportunities. Novel biomarker development is paramount to deliver personalized cancer therapies. Further, tumor evolution, being natural or under treatment pressure, should be monitored and "liquid biopsies" by detecting circulating tumor cells or circulating free tumor DNA in blood samples will become an important option. This paper reviews the new generation of biomarkers and the current evidence to demonstrate their analytical validity, clinical validity and clinical utility.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA ; Department of Medical Oncology, Eugène Marquis Cancer Center, Rennes, France.
- Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
- Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA ; Department of Systems Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Le Du, F., Ueno, N. T., & Gonzalez-Angulo, A. M. (2013). Breast Cancer Biomarkers: Utility in Clinical Practice. Current Breast Cancer Reports, 5(4), 284-292. https://doi.org/10.1007/s12609-013-0125-9
Vancouver
Le Du F, Ueno NT, Gonzalez-Angulo AM. Breast Cancer Biomarkers: Utility in Clinical Practice. Current Breast Cancer Reports. 2013;5(4):284-292. doi:10.1007/s12609-013-0125-9
BibTeX
@article{LeDu2013,
author = {Le Du, Fanny and Ueno, Naoto T and Gonzalez-Angulo, Ana M},
title = {Breast Cancer Biomarkers: Utility in Clinical Practice},
journal = {Current Breast Cancer Reports},
year = {2013},
volume = {5},
number = {4},
pages = {284--292},
doi = {10.1007/s12609-013-0125-9}
}
EUVIMED